Blog
RSS FeedPosted by Michael Wonder on 10 Feb 2022
Theragnostics announces that its radiotherapeutic for treatment of glioblastoma multiforme has been awarded UK's MHRA innovation passport
10 February 2022 - Promising non-clinical results support Phase 1 clinical study in recurrent glioblastoma multiforme. ...
Posted by Michael Wonder on 10 Feb 2022
Eli Lilly promises 40% discount for Innovent’s PD-1 in last-ditch bid to shift FDA review to drug pricing
10 February 2022 - Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics partnered PD-1 ...
Posted by Michael Wonder on 10 Feb 2022
Biden puts focus on drug prices in fight against inflation
10 February 2022 - President Joe Biden is trying to jump-start progress on his stalled domestic agenda by refocusing attention on ...
Posted by Michael Wonder on 10 Feb 2022
A new way to contain unaffordable medication costs - exercising the Government’s existing rights
9 February 2022 - Existing laws could be used to help make many drugs more affordable. ...
Posted by Michael Wonder on 09 Feb 2022
EU ramps up collection of public health data to improve drug reviews
9 February 2022 - By 2025, centre is set to conduct over 100 studies per year. ...
Posted by Michael Wonder on 09 Feb 2022
FDA raises concerns about China developed drugs
9 February 2022 - Agency could slow the plans of big Western drugmakers to sell Chinese tested medicines in U.S. ...
Posted by Michael Wonder on 09 Feb 2022
Initiation of DARWIN EU Coordination Centre advances integration of real world evidence into assessment of medicines in the EU
9 February 2022 - EMA is initiating today the establishment of the Coordination Centre for the Data Analysis and Real ...
Posted by Michael Wonder on 06 Feb 2022
Importing oncology trials from China: a bridge over troubled waters?
4 February 2022 - On 10 February 2022, the US FDA's Oncologic Drugs Advisory Committee will convene to discuss ORIENT-11, a ...
Posted by Michael Wonder on 05 Feb 2022
Confirming the next FDA commissioner is a matter of national preparedness
5 February 2022 - The COVD-19 pandemic has shown in bold relief our lack of national preparedness in the realm of ...
Posted by Michael Wonder on 04 Feb 2022
To hell and back: devices meant to ease pain are causing trauma
5 February 2022 - A $35,000 treatment at the forefront of medical technology which pumps electric pulses into the spine ...
Posted by Michael Wonder on 04 Feb 2022
Lawmakers grill key FDA official over controversial Alzheimer’s drug approval
3 February 2022 - The FDA can’t escape questions about Aduhelm. ...
Posted by Michael Wonder on 03 Feb 2022
Britain fines firms $47 million over price surge for NHS nausea pill
3 February 2022 - Britain's competition watchdog on Thursday fined five firms a total of 35 million pounds ($47.5 million) ...
Posted by Michael Wonder on 03 Feb 2022
Democrats must get their act together, starting with drug prices
3 February 2022 - It's certainly disappointing that President Biden's Build Back Better Act has stalled in the Senate. Democrats were ...
Posted by Michael Wonder on 02 Feb 2022
UK’s Early Access to Medicines Scheme now to be put on a legal footing
2 February 2022 - Significant clarification of the life-changing Early Access to Medicines Scheme to be introduced into law. ...
Posted by Michael Wonder on 02 Feb 2022
Global consequences of the US FDA's accelerated approval of cancer drugs
1 February 2022 - The accelerated approval system is a fast track drug approval pathway created by the US FDA in ...